Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Maetzler, Walter ^a,b   Tian, Youyong ^a,b,d   Baur, Stephanie Maria ^a,b   Gauger, Tina ^a,b   Odoj, Bartholomäus ^a,b   Schmid, Benjamin ^a,b   Schulte, Claudia ^a,b   Deuschle, Christian ^a,b   Heck, Susanna ^a,b   Apel, Anja ^a,b   Melms, Arthur ^c   Gasser, Thomas ^a,b   Berg, Daniela ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; LIGAND; PREALBUMIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEMOGRAPHY; DIFFUSE LEWY BODY DISEASE; FEMALE; GENETIC ASSOCIATION; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FOLDING; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; COHORT STUDIES; DEMENTIA; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; LEWY BODY DISEASE; LIGANDS; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PREALBUMIN;

EID: 84868122315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048042     Document Type: Article

References (54)

1. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, et al. (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-819.
2. Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, et al. (2012) Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71: 258-266.
3. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA, (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64: 1404-1410.
4. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, et al. (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34: 107-112.
5. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330: 1774.
6. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, et al. (2006) Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 21: 45-49.
7. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90: 8098-8102.
8. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, et al. (1993) The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293 (Pt 1): 27-30.
9. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, et al. (2009) Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 14: 493-501.
10. Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, et al. (2011) Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 27: 119-126.
11. Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, et al. (2010) Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis 22: 933-938.
12. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, et al. (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 38: 649-652.
13. Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, et al. (2010) The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 19: 937-942.
14. Li X, Buxbaum JN, (2011) Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener 6: 79.
15. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, et al. (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91: 8368-8372.
16. Deleidi M, Maetzler W (2012) Protein clearance mechanisms of alpha-synuclein and amyloid-beta as potential biomarker sources in Lewy body disorders. Int J Alzheimer's Disease doi:10.1155/2012/391438.
17. Tsuzuki T, Mita S, Maeda S, Araki S, Shimada K, (1985) Structure of the human prealbumin gene. J Biol Chem 260: 12224-12227.
18. Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, et al. (1990) Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol 258: R338-345.
19. Li X, Masliah E, Reixach N, Buxbaum JN, (2011) Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J Neurosci 31: 12483-12490.
20. Du J, Cho PY, Yang DT, Murphy RM, (2012) Identification of beta-amyloid-binding sites on transthyretin. Protein Eng Des Sel 25: 337-345.
21. Costa R, Goncalves A, Saraiva MJ, Cardoso I, (2008) Transthyretin binding to A-Beta peptide-impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582: 936-942.
22. Velayudhan L, Killick R, Hye A, Kinsey A, Guentert A, et al. (2012) Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 28: 369-375.
23. Han SH, Jung ES, Sohn JH, Hong HJ, Hong HS, et al. (2011) Human serum transthyretin levels correlate inversely with Alzheimer's disease. J Alzheimers Dis 25: 77-84.
24. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, et al. (2008) Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14: 17-25.
25. Serot JM, Christmann D, Dubost T, Couturier M, (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 63: 506-508.
26. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234.
27. Guerreiro A, da Costa G, Gomes RA, Ribeiro-Silva C, Gilberto S, et al. (2012) alpha-Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker. Amyloid 19: 74-80.
28. Ruano D, Macedo A, Soares MJ, Valente J, Azevedo MH, et al. (2007) Transthyretin: no association between serum levels or gene variants and schizophrenia. J Psychiatr Res 41: 667-672.
29. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, et al. (2011) Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging 32: 249-256.
30. Natunen T, Helisalmi S, Vepsalainen S, Sarajarvi T, Antikainen L, et al. (2012) Genetic analysis of genes involved in amyloid-beta degradation and clearance in Alzheimer's disease. J Alzheimers Dis 28: 553-559.
31. Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, et al. (2010) A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet 11: 130.
32. Gibb WR, Lees AJ, (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 38: 1402-1406.
33. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, et al. (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-1707.
34. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
35. Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, et al. (2011) Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 26: 176-181.
36. Hixson JE, Vernier DT, (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545-548.
37. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, et al. (1999) Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 13: 273-279.
38. Bohnen NI, Muller ML, Kuwabara H, Constantine GM, Studenski SA, (2009) Age-associated leukoaraiosis and cortical cholinergic deafferentation. Neurology 72: 1411-1416.
39. Bohnen NI, Muller ML, Zarzhevsky N, Koeppe RA, Bogan CW, et al. (2011) Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 134: 2358-2365.
40. Shirahama T, Skinner M, Westermark P, Rubinow A, Cohen AS, et al. (1982) Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am J Pathol 107: 41-50.
41. Vicente Miranda H, Outeiro TF, (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 221: 13-25.
42. Santos SD, Lambertsen KL, Clausen BH, Akinc A, Alvarez R, et al. (2010) CSF transthyretin neuroprotection in a mouse model of brain ischemia. J Neurochem 115: 1434-1444.
43. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM, (1993) CSF transthyretin in patients with depression. Am J Psychiatry 150: 813-815.
44. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, et al. (2010) Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42: 104-111.
45. Tumani H, Pfeifle M, Lehmensiek V, Rau D, Mogel H, et al. (2009) Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid. J Neuroimmunol 214: 109-112.
46. Zhang HL, Zhang XM, Mao XJ, Deng H, Li HF, et al. (2012) Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurol Scand 125: 129-135.
47. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, et al. (2009) Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barre syndrome and other neurological disorders. Clin Chim Acta 405: 143-147.
48. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, et al. (2008) Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 105: 2681-2686.
49. Riisoen H, (1988) Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 78: 455-459.
50. Elovaara I, Maury CP, Palo J, (1986) Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome. Acta Neurol Scand 74: 245-250.
51. Carriere I, Dupuy AM, Lacroux A, Cristol JP, Delcourt C, (2008) Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc 56: 840-846.
52. Myron Johnson A, Merlini G, Sheldon J, Ichihara K, (2007) Scientific Division Committee on Plasma Proteins IFoCC, et al (2007) Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 45: 419-426.
53. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, et al. (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240.
54. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, et al. (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69: 570-580.